Prolight Diagnostics publishes year-end report 2023
Financial overview Fourth quarter, 1 October – 31 December, Q4 2023 Group(figures in the brackets refer to the corresponding period in previous year) • Net sales amounted to 0 (0).• Other operating income amounted to kSEK 5,941 (2,051).• The profit after tax amounted to kSEK -2,382 (-2,809).• Earnings per share before and after dillution: SEK […]
Prolight’s Board of Directors have decided to carry out a directed issue of units to underwriters in connection with the completed rights issue
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE ADDITIONAL REGISTRATION OR OTHER MEASURES. Prolight […]
Prolight announces outcome in the rights issue
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE ADDITIONAL REGISTRATION OR OTHER MEASURES. Prolight […]
Prolight Diagnostics publishes quarterly report Q3, 2023
Financial overviewThird quarter, 1 July – 30 September, Q3 2023 Group (figures in the brackets refer to the corresponding period in previous year) Net sales amounted to 0 (0). Other operating income amounted to kSEK 28 (2,100). The profit after tax amounted to kSEK -9,755 (-5,178). Earnings per share before and after dillution: SEK -0.03 […]
The Board of Directors of Prolight Diagnostics AB (publ) resolves on a rights issue of units of approximately SEK 98.8 million and proposes a directed issue of shares of approximately SEK 20.9 million
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE ADDITIONAL REGISTRATION OR OTHER MEASURES. The […]
Prolight Diagnostics publishes half-year report, 2023
Financial overviewSecond quarter, 1 April – 30 June, Q2 2023 Group Net sales amounted to 0 (0). Other operating income amounted to kSEK 101 (2,311). The profit after tax amounted to kSEK -8,033 (-7,055). Earnings per share before and after dillution: SEK -0.03 (-0.03). Cash flow from current operations was kSEK -8,571 (-10,210). First half-year, […]
Prolight Diagnostics shows proof-of-performance for high-sensitive troponin
Prolight Diagnostics (“Prolight”) today announces that its subsidiary Psyros Diagnostics (“Psyros”) has been able to demonstrate proof-of-performance on its single molecule detection system to reproducibly detect low levels of the troponin protein. These results pave the way for early detection and rule-out of heart attack, which could reduce healthcare costs and improve the quality of […]
Prolight Diagnostics publishes quarterly report Q1, 2023
Financial overviewFirst quarter Q1 2023 Group(figures in brackets only refer to March 2022 as the group was formed on 1 March 2022) Net sales amounted to 0. Other operating income amounted toKSEK 39 (1,298). The profit after tax amounted to kSEK –7,580 (-3,675) Earnings per share before and after dilution: SEK-0.03 (-0.02). Cash flow from […]
Prolight Diagnostics publishes year-end report 2022
Financial overviewFourth quarter Q4 2022 GroupFormed March 1, 2022 Other operating income amounted to kSEK 2,050. The profit after tax amounted to kSEK -2,809. Earnings per share before and after dilution: SEK -0.01. Cash flow from current operations was kSEK -5,436. Cash and cash equivalents amounted to kSEK 54,111 as of December 31, 2022. Fourth […]
Prolight Diagnostics shows proof-of-performance for high-sensitive immuno assay
Prolight Diagnostics (“Prolight”) today announced that its subsidiary Psyros Diagnostics (“Psyros”) has been able to demonstrate proof-of-performance that its high-sensitivity immunoassay is capable of reproducibly detecting low levels of specific proteins in a digital manner. “This is a very important step on our journey to develop a high-sensitivity assay for digitally detecting troponin. Such an […]
